Publications - SFB 1479

Selected publications of the first funding period at a glance.

PIs of CRC1479 are first or last author and CRC1479 funding is indicated in the acknowledgement

Vinnakota JM et al. Nature Cancer 2024 doi: 10.1038/s43018-024-00764-7
Schmitt M et al. Nature 2022 doi: 10.1038/s41586-022-05426-1
Masuda T et al. Nature 2022 doi: 10.1038/s41586-022-04596-2
Friedrich M et al. Nature Cancer 2022 doi: 10.1038/s43018-021-00201-z
Sankowski R et al. Nature Medicine 2024 doi: 10.1038/s41591-023-02673-1
Wertheimer T et al. Nature Immunol. 2024 doi: 10.1038/s41590-024-01755-7
Maas-Bauer K et al. Nature Commun. 2024 doi: 10.1038/s41467-024-44703-7
Velasco Cárdenas RM et al. Nature Immunol. 2023 doi: 10.1038/s41590-023-01658
Zhang YW et al. Nature Cell Biology 2022 doi: 10.1038/s41556-022-00931-x
Ho J et al. Blood 2022 doi: 10.1182/blood.2022016082
Rückert T et al. Sci Transl Med. 2022 doi: 10.1126/scitranslmed.abp9675
Talvard-Balland N et al. J Clin Invest. 2024 doi: 10.1172/JCI177460
Denk D et al. Immunity 2022 doi: 10.1016/j.immuni.2022.09.014
Schmidt D et al. Cancer Res. 2024 doi: 10.1158/0008-5472.CAN-23-3553
Nicolas AM et al. Cancer Cell. 2022 doi: 10.1016/j.ccell.2022.01.004
Grünwald BT et al. Cell 2021 doi: 10.1016/j.cell.2021.09.022
Vinnakota JM et al. Sci Transl Med. 2024 doi: 10.1126/scitranslmed.adj9672
Edwards-Hicks J et al. Nature Immunol. 2023 doi: 10.1038/s41590-023-01419
Saller BS et al. Immunity 2024 doi: 10.1016/j.immuni.2024.10.012
Heim K et al. Nature Immunol. 2024 doi: 10.1038/s41590-024-01928-4
Gallage S et al. Cell Metab. 2024 doi: 10.1016/j.cmet.2024.04.015
Zhang Z et al. Nature Immunol. 2025 doi: 10.1038/s41590-024-02027-0
Braun L et al. Cancer Cell. 2025 doi: 10.1016/j.ccell.2025.01.004
Denk D et al. Immunity 2025 doi: 10.1016/j.immuni.2025.02.005
Gorantla SP et al. Nature Commun 2025 doi: 10.1038/s41467-025-60019-6
Scherer N. et al. Nature Genet. 2025 doi: 10.1038/s41588-024-01965-7
Chatterjee S et al. J Exp Med 2025 doi: 10.1084/jem.20242180
Ardura-Fabregat A et al. Nature Neurosci. 2025 doi: 10.1038/s41593-025-02006-0
Leiloti et al. Nature Cell Biology 2025 doi: 10.1038/s41556-025-01709-7

Publications based on CRC1479 funding

Lalioti ME, Romero-Mulero MC, Karabacz N, Mess J, Demollin H, Rettkowski J, Schuldes K, Mitterer M, Wadle C, Shoumariyeh K, Egg M, Alfonso-Gonzalez C, Jäcklein K, Schönberger K, Karantzelis N, Reisig G, Aktories P, Mayer IM, Tsoukala I, Schäffer A, Tirado-Gonzalez I, Dugourd A, Braun LM, Silva-Rego B, Jones MJ, Kierdorf K, Saez-Rodriguez J, Reising K, Walter SG, Medyouf H, Hilgers V, Ghiaur G, Zeiser R, Karpova D, Renders S, Gravius S, Buescher J, Cabezas-Wallscheid N. Differentiation, ageing and leukaemia alter the metabolic profile of human bone marrow haematopoietic stem and progenitor cells. Nat Cell Biol. 2025 Jul 15. doi: 10.1038/s41556-025-01709-7. Epub ahead of print.

Ardura-Fabregat A, Bosch LFP, Wogram E, Mossad O, Sankowski R, Aktories P, Kieger L, Cook J, Hasavci D, Ulupinar H, Brock D, Wang F, Iovino N, Wald S, Preissl S, Yilmaz B, Schnepf D, Macpherson AJ, Blank T, Kierdorf K, Prinz M. Response of spatially defined microglia states with distinct chromatin accessibility in a mouse model of Alzheimer’s disease. Nat Neurosci. 2025 Jul 14. doi: 10.1038/s41593-025-02006-0. Epub ahead of print.

Chatterjee S, Rückert T, Martin I, Michaeli E, Buescher J, Apostolova P, Erny D, Lalioti ME, Biavasco F, Hartmann A, Runge S, Braun LM, Talvard-Balland N, Adams RC, Schmitt-Graeff A, Cook J, Wenger V, Athanassopoulos D, Hasavci D, Vallejo-Janeta AP, Blank T, Schaible P, Vinnakota JM, Zähringer A, Ganal-Vonarburg SC, Melchinger W, Pfeifer D, Köhler N, Rosshart SP, Michonneau D, Socié G, Andrieux G, Cabezas-Wallscheid N, Boerries M, Prinz M, Zeiser R. Gut microbiota-derived TMAVA is a modulator of acute CNS-GVHD. J Exp Med. 2025 Sep 1;222(9):e20242180. doi: 10.1084/jem.20242180. Epub 2025 Jul 8.

Peighambari A, Huang H, Metzger P, Adlesic M, Zodel K, Schäfer S, Seidel P, Braun LM, Hülsdünker J, Melchinger W, Follo M, Ku M, Haug S, Li Y, Köttgen A, Schell C, von Elverfeldt D, Reichardt W, Zeiser R, Heikenwalder M, Höfflin R, Börries M, Frew IJ. Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance. Sci Rep. 2025 Jun 5;15(1):19818. doi: 10.1038/s41598-025-04917-1.

Gorantla SP, Rassner M, Crossley KA, Müller TA, Poggio T, Khaja Saleem S, Kleinfelder H, Gambheer SMM, Endres C, Schaberg S, Schmidt D, Prince G, Gonzalez-Menendez I, Bentrop D, Trittler R, Rylova S, Pfeifer D, Andrieux G, Quintanilla-Martinez L, Illert AL, von Bubnoff N, Zeiser R, Duyster J. Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling. Nat Commun. 2025 May 24;16(1):4833. doi: 10.1038/s41467-025-60019-6.

Ho NHJG, Talvard-Balland N, Köhler N, Zeiser R. Immune Escape of Acute Myeloid Leukemia after Transplantation. Blood Cancer Discov. 2025 May 5;6(3):168-181. doi: 10.1158/2643-3230.BCD-24-0063.

Zähringer A, Morgado I, Erny D, Ingelfinger F, Gawron J, Chatterjee S, Wenger V, Schmidt D, Schwöbel LF, Adams RC, Langenbach M, Hartmann A, Osswald N, Wolf J, Schlunck G, Briquez PS, Grueter K, Ruess DA, Frew I, Burk AC, Holzmüller V, Grimbacher B, Michonneau D, Andrieux G, Socié G, Kolter J, Börries M, Follo M, Blaeschke F, Sevenich L, Prinz M, Zeiser R, Vinnakota JM. AhR activation mitigates graft-versus-host disease of the central nervous system by reducing microglial NF-κB signaling. Blood Adv. 2025 Mar 31:bloodadvances.2024015000. doi: 10.1182/bloodadvances.2024015000. Epub ahead of print.

Denk D, Ramakrishnan M, Conche C, Pallangyo C, Pesic M, Ceteci F, Kennel KB, Kirisözü AC, Engel E, Mohs K, Ritter B, Pardo AM, Özkurt E, Hildebrand F, Waisman A, Arkan MC, Greten FR. IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis. Immunity. 2025 Mar 11;58(3):701-715.e8. doi: 10.1016/j.immuni.2025.02.005. Epub 2025 Feb 28.

Rodov A, Baniadam H, Zeiser R, Amit I, Yosef N, Wertheimer T, Ingelfinger F. Towards the Next Generation of Data-Driven Therapeutics Using Spatially Resolved Single-Cell Technologies and Generative AI. Eur J Immunol. 2025 Feb;55(2):e202451234. doi: 10.1002/eji.202451234.

Müller M, Zodel K, Abhari BA, Cuomo F, Nizamuddin S, Metzger P, Boerries M, Timmers HTM, Frew IJ. KDM5C and KDM5D mutations have different consequences in clear cell renal cell carcinoma cells. Commun Biol. 2025 Feb 15;8(1):244. doi: 10.1038/s42003-025-07695-8.

Braun LM, Giesler S, Andrieux G, Riemer R, Talvard-Balland N, Duquesne S, Rückert T, Unger S, Kreutmair S, Zwick M, Follo M, Hartmann A, Osswald N, Melchinger W, Chapman S, Hutchinson JA, Haferkamp S, Torster L, Kött J, Gebhardt C, Hellwig D, Karantzelis N, Wallrabenstein T, Lowinus T, Yücel M, Brehm N, Rawluk J, Pfeifer D, Bronsert P, Rogg M, Mattern S, Heikenwälder M, Fusco S, Malek NP, Singer S, Schmitt-Graeff A, Ceteci F, Greten FR, Blazar BR, Boerries M, Köhler N, Duyster J, Ihorst G, Lassmann S, Keye P, Minguet S, Schadendorf D, Ugurel S, Rafei-Shamsabadi D, Thimme R, Hasselblatt P, Bengsch B, Schell C, Pearce EL, Meiss F, Becher B, Funke-Lorenz C, Placke JM, Apostolova P, Zeiser R. Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer Cell. 2025 Feb 10;43(2):269-291.e19. doi: 10.1016/j.ccell.2025.01.004.

Scherer N, Fässler D, Borisov O, Cheng Y, Schlosser P, Wuttke M, Haug S, Li Y, Telkämper F, Patil S, Meiselbach H, Wong C, Berger U, Sekula P, Hoppmann A, Schultheiss UT, Mozaffari S, Xi Y, Graham R, Schmidts M, Köttgen M, Oefner PJ, Knauf F, Eckardt KU, Grünert SC, Estrada K, Thiele I, Hertel J, Köttgen A. Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet. 2025 Jan;57(1):193-205. doi: 10.1038/s41588-024-01965-7. Epub 2025 Jan 2.

Publications based on CRC1479 funding

Contact